Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
21 12 2022
Historique:
pubmed: 15 11 2022
medline: 28 12 2022
entrez: 14 11 2022
Statut: ppublish

Résumé

We investigated the temporal profile of multiple components of the serological response after asymptomatic or mildly symptomatic SARS-CoV-2 infection, in a cohort of 67 previously SARS-CoV-2 naive young adults, up to 8.5 months after infection. We found a significant decrease of spike IgG and neutralization antibody titers from early (11 to 56 days) to late (4 to 8.5 months) time points postinfection. Over the study period, S1-specific IgG levels declined significantly faster than that of the S2-specific IgG. Further, serum antibodies from PCR-confirmed participants cross-recognized S2, but not S1, of the betacoronaviruses HKU1 and OC43, suggesting a greater degree of cross-reactivity of S2 among betacoronaviruses. Antibody-Dependent Natural Killer cell Activation (ADNKA) was detected at the early time point but significantly decreased at the late time point. Induction of serum Antibody-Dependent Monocyte Phagocytosis (ADMP) was detected in all the infected participants, and its levels remained stable over time. Additionally, a reduced percentage of participants had detectable neutralizing activity against the Beta (50%), Gamma (61 to 67%), and Delta (90 to 94%) variants, both early and late postinfection, compared to the ancestral strain (100%). Antibody binding to S1 and RBD of Beta, Gamma, Delta (1.7 to 2.3-fold decrease), and Omicron (10 to 16-fold decrease) variants was also significantly reduced compared to the ancestral SARS-CoV-2 strain. Overall, we found variable temporal profiles of specific components and functionality of the serological response to SARS-CoV-2 in young adults, which is characterized by lasting, but decreased, neutralizing activity and antibody binding to S1, stable ADMP activity, and relatively stable S2-specific IgG levels.

Identifiants

pubmed: 36374040
doi: 10.1128/spectrum.01837-22
pmc: PMC9769986
doi:

Substances chimiques

COVID-19 Vaccines 0
Immunoglobulin G 0
Antibodies, Viral 0
Antibodies, Neutralizing 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0183722

Auteurs

Sindhu Vangeti (S)

Department of Neurology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
Precision Immunology Institute, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
Stockholm University, Stockholm, Sweden.

Sivakumar Periasamy (S)

Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Galveston National Laboratory, Galveston, Texas, USA.

Peifang Sun (P)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.

Corey A Balinsky (CA)

Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.

Avinash S Mahajan (AS)

Department of Neurology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.

Natalia A Kuzmina (NA)

Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Galveston National Laboratory, Galveston, Texas, USA.

Alessandra Soares-Schanoski (A)

Department of Neurology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.

Elizabeth Cooper (E)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.

Charmagne Beckett (C)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.

Jan Marayag (J)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.

Amethyst Marrone (A)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.

Edgar Nunez (E)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.

Yongchao Ge (Y)

Department of Neurology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.

Chad K Porter (CK)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.

Carl W Goforth (CW)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.

Stephen E Lizewski (SE)

Naval Medical Research Unit 6, Lima, Peru.

Rhonda Lizewski (R)

Naval Medical Research Unit 6, Lima, Peru.

Vihasi Jani (V)

Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.

Victor A Sugiharto (VA)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.

Megan Schilling (M)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.

Xuechen B Yu (XB)

Department of Neurology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.

Nada Marjanovic (N)

Department of Neurology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.

Mary Catherine George (MC)

Department of Neurology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.

Alexander Bukreyev (A)

Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Galveston National Laboratory, Galveston, Texas, USA.
Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas, USA.

Stuart C Sealfon (SC)

Department of Neurology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.

Andrew G Letizia (AG)

Naval Medical Research Centergrid.415913.b, Silver Spring, Maryland, USA.
Naval Medical Research Unit-2, Asia, Singapore.

Irene Ramos (I)

Department of Neurology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
Precision Immunology Institute, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH